

Yu-Shan Wu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9109124/publications.pdf>

Version: 2024-02-01

21
papers

441
citations

840776

11
h-index

752698

20
g-index

21
all docs

21
docs citations

21
times ranked

670
citing authors

#	ARTICLE	IF	CITATIONS
1	3,5,2,4-Tetramethoxystilbene, a fully methylated resveratrol analog, prevents platelet aggregation and thrombus formation by targeting the protease-activated receptor 4 pathway. <i>Chemico-Biological Interactions</i> , 2022, 357, 109889.	4.0	7
2	The multi-targeted tyrosine kinase inhibitor SKLB610 resensitizes ABCG2-overexpressing multidrug-resistant cancer cells to chemotherapeutic drugs. <i>Biomedicine and Pharmacotherapy</i> , 2022, 149, 112922.	5.6	4
3	P-glycoprotein Mediates Resistance to the Anaplastic Lymphoma Kinase Inhibitor Ensartinib in Cancer Cells. <i>Cancers</i> , 2022, 14, 2341.	3.7	6
4	Branebrutinib (BMS-986195), a Bruton's Tyrosine Kinase Inhibitor, Resensitizes P-Glycoprotein-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Agents. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 699571.	3.7	3
5	The Second-Generation PIM Kinase Inhibitor TP-3654 Resensitizes ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Cytotoxic Anticancer Drugs. <i>International Journal of Molecular Sciences</i> , 2021, 22, 9440.	4.1	3
6	Sophoraflavanone G Resensitizes ABCG2-Overexpressing Multidrug-Resistant Non-Small-Cell Lung Cancer Cells to Chemotherapeutic Drugs. <i>Journal of Natural Products</i> , 2021, 84, 2544-2553.	3.0	7
7	Erdafitinib Resensitizes ABCB1-Overexpressing Multidrug-Resistant Cancer Cells to Cytotoxic Anticancer Drugs. <i>Cancers</i> , 2020, 12, 1366.	3.7	23
8	Sitravatinib Sensitizes ABCB1- and ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Drugs. <i>Cancers</i> , 2020, 12, 195.	3.7	25
9	SIS3, a specific inhibitor of Smad3 reverses ABCB1- and ABCG2-mediated multidrug resistance in cancer cell lines. <i>Cancer Letters</i> , 2018, 433, 259-272.	7.2	19
10	Human ATP-binding cassette transporters ABCB1 and ABCG2 confer resistance to histone deacetylase 6 inhibitor ricolinostat (ACY-1215) in cancer cell lines. <i>Biochemical Pharmacology</i> , 2018, 155, 316-325.	4.4	16
11	The positive inotropic agent DPI-201106 selectively reverses ABCB1-mediated multidrug resistance in cancer cell lines. <i>Cancer Letters</i> , 2018, 434, 81-90.	7.2	7
12	SIS3, a specific inhibitor of Smad3, reverses multidrug resistance mediated by ABCB1 and ABCG2 in cancer cell lines. <i>Proceedings for Annual Meeting of the Japanese Pharmacological Society</i> , 2018, WCP2018, PO4-6-24.	0.0	0
13	Study of the inhibitory effects on TNF-induced NF- κ B activation of IMD0354 analogs. <i>Chemical Biology and Drug Design</i> , 2017, 90, 1307-1311.	3.2	6
14	Tyrphostin RG14620 selectively reverses ABCG2-mediated multidrug resistance in cancer cell lines. <i>Cancer Letters</i> , 2017, 409, 56-65.	7.2	18
15	Alpha-Mangostin Reverses Multidrug Resistance by Attenuating the Function of the Multidrug Resistance-Linked ABCG2 Transporter. <i>Molecular Pharmaceutics</i> , 2017, 14, 2805-2814.	4.6	24
16	AC-93253 iodide, a novel Src inhibitor, suppresses NSCLC progression by modulating multiple Src-related signaling pathways. <i>Journal of Hematology and Oncology</i> , 2017, 10, 172.	17.0	11
17	Human ATP-Binding Cassette Transporter ABCG2 Confers Resistance to CUDC-907, a Dual Inhibitor of Histone Deacetylase and Phosphatidylinositol 3-Kinase. <i>Molecular Pharmaceutics</i> , 2016, 13, 784-794.	4.6	29
18	Anthelmintic niclosamide modulates dendritic cells activation and function. <i>Cellular Immunology</i> , 2014, 288, 15-23.	3.0	20

#	ARTICLE	IF	CITATIONS
19	Structure-activity relationship of potent antimicrobial peptide analogs of Ixosin-B amide. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2013, 23, 2929-2932.	2.2	3
20	Discovery of potent antimicrobial peptide analogs of Ixosin-B. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2012, 22, 4185-4188.	2.2	11
21	The Emergence of Drug Transporter-Mediated Multidrug Resistance to Cancer Chemotherapy. <i>Molecular Pharmaceutics</i> , 2011, 8, 1996-2011.	4.6	199